whitepaper
Interview: Stefan Braam, CEO & Founder of Ncardia
Mass production with iPSCs: how Ncardia has pushed the boundaries with high-throughput iPSC research.
List view / Grid view
Hit-to-Lead
whitepaper
Whitepaper: Neuroinflammation study
Neuroinflammation study by combining human iPSC-derived astrocytes and HTRF.
whitepaper
Brochure: Particle analysis re-imagined with the Aura™
Get reproducible and quantitative count, size, morphology and particle ID in one system with the Aura™.
whitepaper
Whitepaper: iPSC manufacturing for drug discovery
Controlled manufacturing of hiPSC-derived cardiomyocytes in stirred-tank bioreactors enabling high-throughput phenotypic screening.
news
Study identifies eight novel coronavirus replication terminators
Scientists reveal eight new molecules, five of which are already US FDA-approved, that can block the polymerase reaction SARS-CoV-2 uses to replicate its genome.
video
Video: Ncardia’s iPSC technology
This Ncardia company presentation will explain how human stem cell technology offers a solution for drug screening as well as cell therapy projects.
video
On-demand webinar: Protein or not? Advanced high throughput aggregate analysis
Protein Or not? Advanced high throughput aggregate analysis with The Aura™ - Find the problem before it happens particle analysis reimagined.
video
On-demand webinar: How to be a spectral superstar – NMR & MS analysis made easy
Software to help synthetic and medicinal chemists process and analyse all their spectral data in a single location.
whitepaper
Case study: Better, faster method development at Janssen
Learn how method development software helped Janssen Pharmaceuticals reduce method development time by 80% with a 25-fold increase in method quality
webinar
Drug repurposing approaches to fast track development of new therapies for COVID-19
26 June 2020 | By Tecan
This webinar described the recent efforts to identify small molecule therapeutics for the treatment of SARS-CoV-2 infection and COVID-19 disease.
news
Promising COVID-19 drug candidate identified by virtual screening
After virtually screening 640 existing drug compounds, researchers have revealed that PC786 potently targets several SARS-CoV-2 receptors, making it a candidate to fight COVID-19.
news
Novel compound could treat type 2 diabetes without common side effects
Two molecules combined into a new substance to treat type 2 diabetes lowered blood sugar in shrew models without causing nausea, vomiting and weight loss.
whitepaper
ebook: The researcher’s guide to measuring binding affinity
Learn why measuring binding affinity is key to helping you decide the next steps in your research and what technologies are available to measure it.
news
Screening reveals nelfinavir and amodiaquine combat COVID-19 in cell cultures
Researchers who screened 136 broad-spectrum antivirals identified six with the most activity against COVID-19 and an optimum combination of two to fight the virus.
whitepaper
ebook: The definitive guide to understanding protein stability
Learn how to measure protein stability, why it’s important, and what the key technologies are available to measure it.
